PatternsRadar
Sign in

ORCHPHARMAOrchid Pharma Limited

NSE
Full chart
1,006.55INR+40.65 (+4.21%)Close · 6 Oct 2026
14 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹6,028 CrMarket cap
695.4P/E (TTM)
49.8%Delivery

Filings & corporate actions

24 results filed
CSV
Next results · Q2 FY27
Expected 5 Nov 2026 – 15 Nov 2026
Estimate: filed 36–46 days after quarter end, last 5 times
2026
  • 14 AugresultsResults · Q1 FY27 · consolidated and standalone-4.5%NSE
  • 21 JulshareholdingShareholding · 30 Jun 2026-2.3%NSE
  • 25 MayresultsResults · Q4 FY26 · consolidated and standalone+1.3%NSE
  • 20 AprshareholdingShareholding · 31 Mar 2026-4.2%NSE
  • 11 FebresultsResults · Q3 FY26 · consolidated and standalone-2.6%NSE
  • 21 JanshareholdingShareholding · 31 Dec 2025-0.7%NSE

Reaction to results · all yearsrose on day 0 in 10 of 24 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2714 Aug 2026-4.5%-0.7%-5.5%2.8×
Q4 FY2625 May 2026+1.3%+17.0%+38.9%1.5×
Q3 FY2611 Feb 2026-2.6%-2.9%-25.8%4.2×
Q2 FY2611 Nov 2025-1.3%+3.5%+1.4%5.1×
Q1 FY2612 Aug 2025+1.2%+3.5%-6.4%1.3×
Q4 FY2528 May 2025-5.0%+2.8%-0.1%4.1×
Q3 FY2513 Feb 2025-15.2%-29.1%-34.7%10.5×
Q2 FY2512 Nov 2024+2.0%+1.7%+17.0%1.8×
Q1 FY2513 Aug 2024-1.5%-2.2%+7.5%0.5×
Q4 FY2424 May 2024-0.2%-2.9%+16.3%1.3×
Q3 FY2410 Feb 2024+3.1%+9.1%+2.4%2.5×
Q2 FY245 Nov 2023+1.9%+10.2%+17.5%1.7×
Q1 FY2411 Aug 2023-4.9%-6.6%-8.6%1.0×
Q4 FY2311 May 2023+4.9%+2.2%+0.5%4.0×
Q3 FY2310 Feb 2023+3.5%+9.5%+4.5%3.6×
Q2 FY2315 Nov 20220.0%-4.1%-9.2%0.7×
Q1 FY2310 Aug 2022-1.0%-1.5%+6.8%1.0×
Q4 FY2213 May 2022+0.4%-4.3%-6.5%0.3×
Q3 FY2213 Feb 2022-2.1%-9.3%-8.9%1.7×
Q2 FY2215 Nov 2021-1.0%-6.0%-5.4%0.5×
Q1 FY2214 Aug 2021-4.7%-10.0%-2.2%0.4×
Q4 FY2123 May 2021-0.3%-3.8%-6.4%0.7×
Q3 FY2110 Feb 2021+5.0%+34.0%+178.4%4.2×
Q2 FY2112 Nov 2020+5.0%+39.9%+188.6%—
Average-0.7%+2.1%+15.0%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+75.9%
Profit YoY-78.4%
Interest cost YoY-14.5%
Revenue QoQ+28.0%
Profit QoQ-86.4%
CAGR2Y3Y4Y5Y6Y7Y
Revenue+3.4%+9.5%+12.0%+17.4%——
Profit-72.1%-50.3%-11.2%———

Key data

CSV
Open967.35
Day range965.00 – 1,015.10
52-week range480.00 – 1,143.50
From 52w high-12.0%
RSI (14)49.5
ATR (14)51.07
Volume65.7K
Avg volume (20D)1.30L
Rel volume0.51×
Volatility (1Y)43.8%
Turnover₹6.6Cr
SMA 50 / 2001,003.58 / 801.44

Delivery percentage

Latest · 6 Oct 202649.8%
20-day avg46.2%
1-year avg48.9%
Percentile (own history)21st
Range9.7–100.0%
Sessions1,463

Over the last 20 sessions ORCHPHARMA settled 46.2% of its traded quantity, which is above average for an NSE equity. Its one-year average is 48.9%, so recent sessions are running 2.7 points lower than usual. The latest session ranks higher than 21% of the 1,463 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+4.21%-1.65%+7.69%+8.86%+92.16%+39.52%

Valuation

CSV
Market cap₹6,028 Cr
P/E (TTM)695.4
EPS (TTM)1.45
Shares outstanding5.99Cr
Listed2 Nov 2020

Ownership

CSV
Promoter69.84%
Promoter Δ QoQ0.00 pp
Public30.16%
FII0.81%
DII20.75%
Pledged0.00%

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)193.5207.3368.3304.2
YoY chg-13.1%-4.6%+55.1%+75.9%
Net profit (₹ Cr)(5.7)(12.6)25.83.2
YoY chg-121.0%-160.7%+15.9%-78.4%
Net margin-3.0%-6.1%7.0%1.1%
EPS-1.13-2.494.310.54

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 69.84% · public 30.16%
30 Sept 2021: promoter 90.00%31 Dec 2021: promoter 90.00%31 Mar 2022: promoter 90.00%30 Jun 2022: promoter 89.96%30 Sept 2022: promoter 89.96%31 Dec 2022: promoter 89.96%31 Mar 2023: promoter 89.96%27 Jun 2023: promoter 72.40%30 Jun 2023: promoter 72.40%30 Sept 2023: promoter 72.40%31 Dec 2023: promoter 69.84%31 Mar 2024: promoter 69.84%30 Jun 2024: promoter 69.84%30 Sept 2024: promoter 69.84%31 Dec 2024: promoter 69.84%31 Mar 2025: promoter 69.84%30 Jun 2025: promoter 69.84%30 Sept 2025: promoter 69.84%31 Dec 2025: promoter 69.84%31 Mar 2026: promoter 69.84%30 Jun 2026: promoter 69.84%
2021-092026-06
  • Promoter
  • Public and others
Promoter
69.84%
Public
30.16%
Promoter change
0.00 pp
Filed
21 Jul 2026
FII
0.81%
DII
20.75%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26ARQ1 FY27
Revenue from operations198.8220.6217.1244.4222.7217.3237.5172.9193.5207.3368.3304.2
Other income8.47.613.47.67.58.53.911.410.85.67.81.8
Total income207.1228.2230.5252.0230.2225.8241.4184.4204.3212.9376.1306.0
Total expenses187.1198.0200.1223.9204.3203.4222.3170.7207.6217.9351.0303.4
└ Finance costs3.83.53.53.53.33.83.93.33.73.22.02.2
└ Depreciation7.89.38.48.48.68.68.98.78.99.010.910.9
Profit before tax20.030.230.428.125.922.519.113.7(3.3)(12.1)24.82.6
Tax expense0.00.0(3.1)(0.2)0.00.0(0.0)0.00.00.00.00.1
Net profit19.829.433.029.427.220.822.314.9(5.7)(12.6)25.83.2
EPS4.306.186.815.795.374.104.402.94-1.13-2.494.310.54
Net margin9.96%13.34%15.18%12.01%12.23%9.56%9.39%8.62%-2.96%-6.09%7.02%1.06%
PBT margin10.07%13.69%13.99%11.51%11.63%10.33%8.04%7.93%-1.72%-5.86%6.75%0.87%
Tax rate0.00%0.00%-10.27%-0.55%0.00%0.00%-0.21%0.00%——0.01%2.73%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 14 Aug 2026.

ORCHPHARMA at a glance

  • ORCHPHARMA closed at ₹1,006.55 on 6 Oct 2026, +4.21% on the day, +39.5% over one year, 12.0% below its 52-week high of ₹1,143.5.
  • Delivery was 49.8% of traded quantity on 6 Oct 2026, the 21st percentile of its own 1,463 sessions with a reading (20-session average 46.2%, 1-year average 48.9%).
  • Market capitalisation is ₹6,028 crore at a trailing P/E of 695.4 (trailing EPS ₹1.45).
  • Q1 FY27 results (consolidated, filed 14 Aug 2026): revenue ₹304 crore (+75.9% year on year), net profit ₹3 crore (-78.4%); the price moved -4.5% on the first session after.
  • Promoters held 69.84% at 30 Jun 2026, unchanged on the previous filing.
  • Q2 FY27 results are expected between 5 Nov 2026 and 15 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE191A01027
SeriesEQ
Listed2 Nov 2020
History from3 Nov 2020
Sessions1,467
Turnover rank#921

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE